Cellyan Biotechnology Ltd. engages in providing pharmaceutical cross-border e-commerce supply chain services. The company employs 27 full-time employees The company went IPO on 2025-01-15. The firm mainly provides two services. The supply chain services mainly provide OTC pharmaceutical cross-border e-commerce supply chain services. The procurement and distribution services mainly provide OTC pharmaceutical cross-border procurement and distribution services.
根据最新的财务报表(Form-10K),Cellyan Biotechnology Co Ltd 的总资产为 $0,净损失为 $0
HKPD 的关键财务比率是什么?
Cellyan Biotechnology Co Ltd 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
Cellyan Biotechnology Co Ltd 的收入按细分市场或地理位置如何划分?
Cellyan Biotechnology Co Ltd 最大收入来源是 Transportation Solutions,在最近的收益报告中收入为 1,747,039,000。就地区而言, United States 是 Cellyan Biotechnology Co Ltd 的主要市场,收入为 1,946,740,000。